Symptomatic Hyponatremia with Hypoxia Is a Medical Emergency

Total Page:16

File Type:pdf, Size:1020Kb

Symptomatic Hyponatremia with Hypoxia Is a Medical Emergency View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector http://www.kidney-international.org commentary © 2006 International Society of Nephrology see original article on page 1319 rection of serum sodium concentration Symptomatic hyponatremia with and one who died in the absence of any therapeutic interventions to correct her hypoxia is a medical emergency hyponatremia.4 We now understand that much heterogeneity exists among 1 JP Kokko patients with hyponatremia. Some patients will tolerate a relatively con- Patients presenting with the combined finding of severe symptomatic servative approach, whereas others are at hyponatremia and hypoxia have such high mortality rates that they high mortality risk if their symptomatic should be admitted to an intensive care unit and intubated sooner rather hyponatremia is not corrected rapidly. than later. Without delay, these patients need rapid correction of their Many clinicians have made important serum sodium by 8–10 mequiv. per liter and an increase in their partial contributions to this area; perhaps the studies of Ayus, Arieff , and their col- pressure of arterial oxygen to values above 70 mm Hg. leagues are most direct in pointing out Kidney International (2006) 69, 1291–1293. doi:10.1038/sj.ki.5000252 that the patients at highest risk are the ones with the combined fi nding of symp- tomatic hyponatremia and hypoxia.5–7 It Hyponatremia is a frequent electro- sodium concentration was rapidly cor- should be noted that neither the early lyte abnormality among hospitalized rected from 106.3 to 151.8 mequiv. per clinical observations (before 1992) nor patients. In general, it is classified as liter with the use of hypertonic saline. animal studies addressed the possible acute (less than 48 hours in duration) Similar fi ndings of CPM could not be adverse eff ect of hypoxia on outcomes in versus chronic (more than 48 hours in duplicated by Ayus and colleagues2 symptomatic hyponatremia. To under- duration). It is further characterized as when hyponatremia in their rats was stand why hypoxia is a severe comorbid asymptomatic versus symptomatic (agi- increased by 14–25 mequiv. per liter in factor requires a paragraph on brain cell tation, depressed sensorium, grand mal the fi rst 24 hours, that is, not overcor- volume regulation. seizures). Th is simple, albeit superfi cial, rected rapidly to values above normal. Essentially all cells have the capacity classifi cation is important, as it suggests However, physicians are taught not to to regulate their volume. Th e regulation an appropriate therapeutic approach to a harm their patients, and therefore the of cell volume by the brain cells is criti- given patient. Before the 1980s, many of fear of CPM caused such concern that cally important because acute swelling us who were in clinical practice felt that many physicians became afraid to of the brain cells is limited by the fi xed if we saw a laboratory abnormality, it treat symptomatic hyponatremia, even skull, which will cause pressure necrosis should be corrected rapidly. However, it when they recognized that failure to and/or transtentorial herniation. On the was becoming evident that patients with treat was associated with high mortal- other hand, rapid shrinkage in response symptomatic hyponatremia had an unac- ity rates. Th is conservative view against to an external hypertonic gradient can ceptably high mortality rate whether rapid correction of plasma sodium con- cause adverse cellular events including they were left untreated or whether centration was supported by a careful putative disruption of controlled mye- their sodium concentration was rapidly paper by Sterns,3 in which he observed lin synthesis and degradation. Cell vol- corrected. In a classic paper published among his 62 patients that the previ- ume regulation has been studied more in 1981,1 Kleinschmidt-DeMasters and ously noted high mortality rates with extensively when cells are challenged to Norenberg reported an experimental symptomatic hyponatremia were not protect their volume by exposure to a study in rats that was based on their pre- nearly as high as some of the literature hypo-osmotic external milieu than when vious clinical experience showing that then suggested if the low sodium con- they are exposed to a hypertonic envi- central pontine myelinolysis (CPM) is an centration was corrected at low versus ronment such as a rapid rise in plasma ‘iatrogenic disorder’ caused by rapid cor- high rates. Nevertheless, many patients sodium concentration. When cells are rection of hyponatremia. Although their were still dying when symptomatic exposed to a hypo-osmotic environment conclusion that CPM is an iatrogenic hyponatremia was left untreated and (hyponatremia), they swell unless there disorder was correct, it should be noted allowed to correct with spontaneous is an appropriate outward movement that in their experiments the rats’ serum water diureses. Th is led Kidney Interna- of intracellular solutes. Th is is largely tional to devote a “Nephrology Forum” accomplished by activation of leak path- 1Department of Medicine, Emory University School to “Treating hyponatremia: damned if way channels that initially allow outward of Medicine, Atlanta, Georgia, USA we do and damned if we don’t,” in which diff usion of potassium and chloride and Correspondence: JP Kokko, Emory University School of Medicine, 69 Jesse Hill, Jr. Drive, Suite 205, Berl described being presented with two later allow outward diff usion of organic Atlanta, Georgia 30303, USA. patients with hyponatremia, one who solutes. It is beyond the scope of this E-mail: [email protected] developed CPM following rapid cor- Commentary to review these processes; Kidney International (2006) 69 1291 commentary the interested reader is directed to an in those patients who had their serum remaining diff erence in sodium concen- excellent review of this topic by Pas- sodium concentration corrected at rates tration. I advise not to raise the sodium antes-Morales and colleagues.8 Many below 0.55 mequiv. per liter per hour.10 concentration much over 120 mequiv. biologic regulatory processes are not So what is the clinician to conclude per liter in the fi rst 24 hours and then symmetric. This certainly is the case from all these studies when faced with to correct the remaining defi cit at a rate when cellular processes are activated to a severely hyponatremic patient? Th ere that improves serum concentration protect the volume of cells exposed to is no question that many asymptomatic each 24 hours by 50% of the desired a hypertonic milieu that would tend to patients with normal arterial oxygen fi nal sodium concentration. One of the shrink them. Under these circumstances saturation and severe hyponatremia do practical issues I have faced in the emer- the cell must gain net solute against elec- well without rapid correction of their gency room is the unavailability of 3% trochemical gradients and requires much serum sodium concentration; how- NaCl or an enormous delay in getting it more oxygen-dependent energy than is ever, it is now clear that symptomatic there. Given the lack of any evidence to provided by activation of outward leak hyponatremic patients, especially if the contrary, I have recommended push- pathway channels. Th us it is evident that they are female and hypoxic with arte- ing an ampoule of NaHCO3 in these conditions in which oxygen availability rial partial pressure of oxygen below circumstances (an ampoule usually con- is limited are just those conditions in 70 mm Hg, should receive rapid cor- tains either 44 or 50 mequiv. NaHCO3); which cells are unable to have suffi cient rection of their sodium concentration this will allow time to get the 3% NaCl inward transport rates of solutes to pro- to safe levels. Th us, to use Berl’s color- delivered. I feel that the weight of the tect against cell shrinkage. ful choice of words,4 one must conclude literature supports initiation of the cor- As they report in this issue,9 Ayus, that we are damned if we don’t, or at rection of the osmolality as soon as it is Armstrong, and Arieff have carried least the patient is. feasible. I make these same therapeutic out an important series of studies that Now comes the important question of recommendations also for patients who extends many of their previous obser- how to administer the sodium, and at have symptomatic hyponatremia but vations. Th ey show in three groups of what rate it will decrease the very high normal oxygenation. Although these rodents that hypoxia interferes with mortality associated with the combi- patients do not have the same high risk normal brain cell volume adaptation in nation of hypoxia and hyponatremia. of mortality as hypoxic patients, they response to hyponatremic challenges. In The literature supports the view that nevertheless are at increased risk of hyponatremic animals, hypoxia aggra- the rate of correction should be at least dying. If, on the other hand, the patient vated cerebral edema, decreased cerebral 0.55 mequiv. per liter per hour. It is is hypoxic for any reason (central res- perfusion, and led to histologic abnor- impractical in an acute hospital setting piratory depression secondary to brain malities in the cerebellum, thalamus, to try to calculate accurately how much edema, pneumonia, or any other cause), reticular formation, and basal ganglia.9 sodium to give. First, it is diffi cult to or if the patient’s arterial oxygen begins Many of these histologic fi ndings are obtain accurate patient weights, good to drop during the course of treatment, similar to those that have been noted estimates of total body water, and esti- then he or she should be hospitalized previously to occur when hyponatremia mates of bone weight (approximately in an intensive care unit and intubated has been rapidly corrected.
Recommended publications
  • A Randomized, Double-Blind, Placebo-Controlled Study
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20055715; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Mo%on Sifnos: A randomized, double-blind, placebo-controlled study demonstra%ng the effec%veness of tradipitant in the treatment of mo%on sickness Vasilios M. Polymeropoulos*1, Mark É. Czeisler1#a, Mary M. Gibson1¶, Aus%n A. Anderson1¶, Jane Miglo1#b, Jingyuan Wang1, Changfu Xiao1, Christos M. Polymeropoulos1, Gunther Birznieks1, Mihael H. Polymeropoulos1 1 Vanda Pharmaceu%cals, Washington, District of Columbia, United States of America #a The Ins%tute for Breathing and Sleeping, Aus%n Health, Heidelberg, Victoria, Australia #b College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, United States of America *Corresponding author Email: [email protected] (VMP) ¶These authors contributed equally to this work. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20055715; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 2 Abstract Background Novel therapies are needed for the treatment of mo%on sickness given the inadequate relief, and bothersome and dangerous adverse effects of currently approved therapies.
    [Show full text]
  • Adverse Drug Reactions Sample Chapter
    Sample copyright Pharmaceutical Press www.pharmpress.com 5 Drug-induced skin reactions Anne Lee and John Thomson Introduction Cutaneous drug eruptions are one of the most common types of adverse reaction to drug therapy, with an overall incidence rate of 2–3% in hos- pitalised patients.1–3 Almost any medicine can induce skin reactions, and certain drug classes, such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and antiepileptics, have drug eruption rates approaching 1–5%.4 Although most drug-related skin eruptions are not serious, some are severe and potentially life-threatening. Serious reac- tions include angio-oedema, erythroderma, Stevens–Johnson syndrome and toxic epidermal necrolysis. Drug eruptions can also occur as part of a spectrum of multiorgan involvement, for example in drug-induced sys- temic lupus erythematosus (see Chapter 11). As with other types of drug reaction, the pathogenesis of these eruptions may be either immunological or non-immunological. Healthcare professionals should carefully evalu- ate all drug-associated rashes. It is important that skin reactions are identified and documented in the patient record so that their recurrence can be avoided. This chapter describes common, serious and distinctive cutaneous reactions (excluding contact dermatitis, which may be due to any external irritant, including drugs and excipients), with guidance on diagnosis and management. A cutaneous drug reaction should be suspected in any patient who develops a rash during a course of drug therapy. The reaction may be due to any medicine the patient is currently taking or has recently been exposed to, including prescribed and over-the-counter medicines, herbal or homoeopathic preparations, vaccines or contrast media.
    [Show full text]
  • Chapter 5 Biological Effects of Ionizing Radiation Page I
    CHAPTER 5 BIOLOGICAL EFFECTS OF IONIZING RADIATION PAGE I. Introduction ............................................................................................................................ 5-3 II. Mechanisms of Radiation Damage ........................................................................................ 5-3 A. Direct Action .............................................................................................................. 5-3 B. Indirect Action ........................................................................................................... 5-3 III. Determinants of Biological Effects ........................................................................................ 5-4 A. Rate of Absorption ..................................................................................................... 5-5 B. Area Exposed ............................................................................................................. 5-5 C. Variation in Species and Individual Sensitivity ......................................................... 5-5 D. Variation in Cell Sensitivity ....................................................................................... 5-5 IV. The Dose-Response Curve ..................................................................................................... 5-6 V. Pattern of Biological Effects .................................................................................................. 5-7 A. Prodromal Stage ........................................................................................................
    [Show full text]
  • Acute Radiation Syndrome (ARS) – Treatment of the Reduced Host Defense
    International Journal of General Medicine Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Acute radiation syndrome (ARS) – treatment of the reduced host defense Lars Heslet1 Background: The current radiation threat from the Fukushima power plant accident has prompted Christiane Bay2 rethinking of the contingency plan for prophylaxis and treatment of the acute radiation syndrome Steen Nepper-Christensen3 (ARS). The well-documented effect of the growth factors (granulocyte colony-stimulating factor [G-CSF] and granulocyte-macrophage colony-stimulating factor [GM-CSF]) in acute radia- 1Serendex ApS, Gentofte; 2University of Copenhagen, tion injury has become standard treatment for ARS in the United States, based on the fact that Medical Faculty, Copenhagen; growth factors increase number and functions of both macrophages and granulocytes. 3 Department of Head and Neck Review of the current literature. Surgery, Otorhinolaryngology, Methods: Køge University Hospital, Køge, Results: The lungs have their own host defense system, based on alveolar macrophages. After Denmark radiation exposure to the lungs, resting macrophages can no longer be transformed, not even during systemic administration of growth factors because G-CSF/GM-CSF does not penetrate the alveoli. Under normal circumstances, locally-produced GM-CSF receptors transform resting macrophages into fully immunocompetent dendritic cells in the sealed-off pulmonary compartment. However, GM-CSF is not expressed in radiation injured tissue due to deferves- cence of the macrophages. In order to maintain the macrophage’s important role in host defense after radiation exposure, it is hypothesized that it is necessary to administer the drug exogenously in order to uphold the barrier against exogenous and endogenous infections and possibly prevent the potentially lethal systemic infection, which is the main cause of death in ARS.
    [Show full text]
  • Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor
    J Am Board Fam Pract: first published as 10.3122/jabfm.10.5.370 on 1 September 1997. Downloaded from BRIEF REPORTS Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor Adriana]. Pavietic, MD Angioedema is an uncommon adverse effect of cyclobenzaprine, her angioedema was initially be­ angiotensin-converting enzyme (ACE) inhib­ lieved to be an allergic reaction to this drug, and itors. Its frequency ranges from 0.1 percent in pa­ it was discontinued. She was also given 125 mg of tients on captopril, lisinopril, and quinapril to 0.5 methylprednisolone intramuscularly. Her an­ percent in patients on benazepril. l Most cases are gioedema did not improve, and she returned to mild and occur within the first week of treat­ the clinic the following day. She was seen by an­ ment. 2-4 Recent reports indicate that late-onset other physician, who discontinued lisinopril, and angioedema might be more prevalent than ini­ her symptoms resolved within 24 hours. Mter her tially thought, and fatal cases have been de­ ACE inhibitor was discontinued, she experienced scribed.5-11 Many physicians are not familiar with more symptoms and an increased frequency of late-onset angioedema associated with ACE in­ palpitations, but she had no change in exercise hibitors, and a delayed diagnosis can have poten­ tolerance. A cardiologist was consulted, who pre­ tially serious consequences.5,8-II scribed the angiotensin II receptor antagonist losartan (initially at dosages of 25 mg/d and then Case Report 50 mg/d). The patient was advised to report any A 57-year-old African-American woman with symptoms or signs of angioedema immediately copyright.
    [Show full text]
  • Angioedema, a Life-Threatening Adverse Reaction to ACE-Inhibitors
    DOI: 10.2478/rjr-2019-0023 Romanian Journal of Rhinology, Volume 9, No. 36, October - December 2019 LITERATURE REVIEW Angioedema, a life-threatening adverse reaction to ACE-inhibitors Ramona Ungureanu1, Elena Madalan2 1ENT Department, “Dr. Victor Babes” Diagnostic and Treatment Center, Bucharest, Romania 2Allergology Department, “Dr. Victor Babes” Diagnostic and Treatment Center, Romania ABSTRACT Angioedema with life-threatening site is one of the most impressive and serious reasons for presenting to the ENT doctor. Among different causes (tumors, local infections, allergy reactions), an important cause is the side-effect of the angiotensin converting enzyme (ACE) inhibitors drugs. ACE-inhibitors-induced angioedema is described to be the most frequent form of bradykinin- mediated angioedema presented in emergency and also one of the most encountered drug-induced angioedema. The edema can involve one or more areas of the head and neck region, the most affected being the face, the lips, the tongue, followed by the larynx, when it may determine respiratory distress and even death. There are no specific diagnosis tests available and the positive diagnosis of ACE-inhibitors-induced angioedema is an exclusion diagnosis. The authors performed a review of the most important characteristics of the angioedema caused by ACE-inhibitors and present their experience emphasizing the diagnostic algorithm. KEYWORDS: angioedema, ACE-inhibitors, hereditary angioedema, bradykinin, histamine. INTRODUCTION with secondary local extravasation of plasma and tissue swelling5,6. Angioedema (AE) is a life-threatening condition Based on this pathomechanism, the classification presented as an asymmetric, localised, well-demar- of angioedema comprises three major types: 1). cated swelling1, located in the mucosal and submu- bradykinin-mediated – with either complement C1 cosal layers of the upper respiratory airways.
    [Show full text]
  • Pilot Study to Assess Outcomes of a Drug Allergy Clarification Service on a General Medicine Floor at a Local Community Hospital Crystal M
    Original Research PRACTICE-BASED RESEARCH Pilot Study to Assess Outcomes of a Drug Allergy Clarification Service on a General Medicine Floor at a Local Community Hospital Crystal M. Deas, PharmD, BCPS1; C. Whitney White, PharmD, BCPS2 1Samford University, McWhorter School of Pharmacy, Clinical Pharmacist, Cooper Green Mercy Health Services, Birmingham, AL 2University of Mississippi School of Pharmacy, University of Mississippi Medical Center, Jackson, MS Abstract Purpose: Drug allergy documentation in the patient medical record varies in level of detail, and drug intolerances are often inappropriately documented as an allergy in the medical record. A pilot study was conducted to determine the impact of a pharmacy- led drug allergy clarification service. Methods: The pilot quality improvement service was implemented in Fall 2016. General medicine patients were identified through daily census reporting and the electronic medical record (EMR) was reviewed within 72 hours of admission for documented drug allergies and/or intolerances. Patients were interviewed by a clinical pharmacist or a fourth year pharmacy student to determine a complete drug allergy and intolerance history. Results: A total of 55 patients were interviewed and received the pilot service. A drug allergy/intolerance was documented in EMR for 54.5% (n=30) of patients interviewed. Of those 30 patients, 96.6% (n=29) were noted to have at least one discrepancy between EMR documentation and patient interview. The primary discrepancy noted was drug allergies or intolerances documented in the EMR without a description of the reaction. Conclusion: A pharmacy-led drug allergy clarification service was effective in identifying and clarifying EMR documentation of patients’ drug allergies and intolerances.
    [Show full text]
  • NIH Public Access Author Manuscript Neurocrit Care
    NIH Public Access Author Manuscript Neurocrit Care. Author manuscript; available in PMC 2013 June 10. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Neurocrit Care. 2012 December ; 17(3): 441–467. doi:10.1007/s12028-012-9747-4. Brain Resuscitation in the Drowning Victim Alexis A. Topjian, The Children’s Hospital of Philadelphia, 7th floor, 34th Street and Civic Center Boulevard, Suite 7C23, Philadelphia, PA 19104, USA, [email protected] Robert A. Berg, The Children’s Hospital of Philadelphia, 7th floor, 34th Street and Civic Center Boulevard, Suite 7C23, Philadelphia, PA 19104, USA, [email protected] Joost J. L. M. Bierens, Maatschappij tot Redding van Drenkelingen, Amsterdam, The Netherlands, [email protected] Christine M. Branche, National Institute for Occupational Safety and Health/Centers for Disease Control, Washington, DC, USA, [email protected] Robert S. Clark, Children’s Hospital of Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, PA, USA, [email protected] Hans Friberg, Department of Intensive and Perioperative Care, Skåne University Hospital, Lund, Sweden, [email protected]; Department of Clinical Sciences, Lund University, 221 85 Lund, Sweden Cornelia W. E. Hoedemaekers, Department of ICU, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands, [email protected] Michael Holzer, Department of Emergency Medicine, Medical University of Vienna, Waehringer Guertel 18-20/6D, 1090 Vienna, Austria, [email protected] Laurence M. Katz, Department of Emergency Medicine, Neurosciences, University of North Carolina at Chapel Hill, 101 Manning Drive, Chapel Hill, NC 27599, USA, [email protected] Johannes T.
    [Show full text]
  • About Drug Side-Effects and Allergies
    About drug side-effects and allergies Introduction This leaflet has been produced to provide you with information about side-effects of medicines and drug allergies, and the differences between the two. There are a variety of ways in which people can experience adverse reactions to medications, whether prescribed or bought 'over-the-counter'. Most of these effects are not an 'allergy'. Contrary to what most people think, only small amounts (5-10%) of all adverse drug reactions are caused by a drug allergy. It is important to tell the doctor or healthcare professional looking after you about any drug allergies or side-effects to drugs you may have/or had as this may affect your current treatment. It is important to know the difference between a drug allergy and side-effect because saying you have a drug allergy when in fact it is a side-effect may unnecessarily restrict the treatment choices available to treat your condition. What should I be aware of when taking my medicines? Many medicines can cause side-effects e.g. some medicines may affect your sight or co-ordination or make you sleepy, which may affect your ability to drive, perform skilled tasks safely. The information leaflet provided with your medicine will list any side effects which are known to be linked to your medicine. All medications have side-effects because of the way they work. The majority of people get none, or very few, but some people are more prone to them. The most common side-effects are usually nausea, vomiting, diarrhoea (or occasionally constipation), tiredness, rashes, itching, headaches and blurred vision.
    [Show full text]
  • Adverse Drug Reaction Reporting
    P T Chapter 40 Adverse Drug Reaction Reporting Lee B. Murdaugh, RPh, PhD The Conditions of Participation standards of the Centers for Medicare & Medicaid Services (CMS) and the standards of accrediting organizations such as The Joint Commission, the Healthcare Facilities Accredi- tation Program (HFAP), and the National Integrated Accreditation for Healthcare Organizations (NIAHOSM) require hospitals to identify and report adverse drug reactions (ADRs). These ADRs must be reported to LEARNING OBJECTIVES patients’ attending physicians and the hospital’s quality assessment and performance improvement program. Additionally, hospitals are expected to report serious • Define an adverse drug reaction. ADRs (as defined by the Food and Drug Administration • Discuss the detection of adverse [FDA]) to the FDA’s MedWatch program and ADRs to vaccines to the FDA’s Vaccine Adverse Events Reporting drug reactions. System (VAERS). • Discuss the assessment of adverse drug reactions. Defining Adverse Drug Reactions To recognize and assess ADRs, there must be a defini- tion of what constitutes an ADR. Examples of commonly used definitions are discussed in the following text. The FDA defines a serious adverse reaction as one in which “the patient outcome is death, life threat- ening (real risk of dying), hospitalization (initial or prolonged), disability (significant, persistent, or perma- nent), congenital anomaly, or required intervention to prevent permanent impairment or damage.”1 The American Society of Health-System Pharma- cists (ASHP) defines a ADR as “any unexpected, unin- tended, undesired, or excessive response to a drug that • requires discontinuing the drug (therapeutic or diagnostic) • requires changing the drug therapy • requires modifying the dose (except for minor dosage adjustments) • necessitates admission to a hospital 546 Competence Assessment Tools for Health-System Pharmacies • prolongs stay in a healthcare facility routine observation and assessment.
    [Show full text]
  • Aabcde System (Adverse Events of Type A, B, C, D, E)
    ABCDE SYSTEM (ADVERSE EVENTS OF TYPE A, B, C, D, E) HISTORY Hurwitz and Wade proposed many years ago four categories of adverse events (Br Med J 1969; Mar 1(643):531). The first two mechanisms have been combined A under category A and the second two mechanisms under category B. I Side effect I Excess effect I Allergy (hypersensitivity) I Idiosyncrasy DeSwarte classified adverse drug reactions (ADRs) into eight categories (Arch Intern Med 1986;146:649): I Overdose I Side effect I Secondary, indirect effect I Interaction I Intolerance I Idiosyncrasy (primary toxicity) I Allergy I Pseudoallergy (anaphylactoid) Note that overdose and interaction are risk factors and the indirect or second- ary effect is a physiologic consequence. Further information can be found in Meyboom (PEDS 1997;16:355) and in Royer (PEDS 1997;6:S43). TYPE A ADVERSE EVENT Rawlins and Thompson of Newcastle, Great Britain, have classified adverse events into type A and type B on the basis of the mechanism of action. A type A event is one that is due to an extension of the active pharmacologic properties of the drug (A indicates augmented). They are also called predictable or anticipated events. They are generally less severe and more frequent than type B events. This augmented pharmacologic action may occur at the targeted receptors or at other nontargeted receptors producing lateral effects, parallel effects, or side effects. They are usually detected during the clinical trials done before marketing. There are two subclasses: ◗ Exaggerated Desired Effect The undesirable exaggeration of a desired pharmacologic effect after a normal dose in a susceptible subject or after a higher than normal dose.
    [Show full text]
  • Severe Recurrent Hypothermia in an Elderly Patient with Refractory Mania
    BMJ Case Reports: first published as 10.1136/bcr-2017-222462 on 2 December 2017. Downloaded from Unexpected outcome (positive or negative) including adverse drug reactions CASE REPORT Severe recurrent hypothermia in an elderly patient with refractory mania associated with atypical antipsychotic, valproic acid and oxcarbazepine therapy Oluwadamilare O Ajayi, Suzanne Holroyd Department of Psychiatry & SUMMARY CASE PRESENTATION Behavioral Medicine, Joan C. Hypothermia is a rare but serious condition that has Our patient is a 76-year-old obese (body mass index Edwards School of Medicine at been associated with various psychiatric medications. 36.6 kg/m2) woman treated on a chronic geriatric Marshall University, Huntington, We present a 76-year-old woman with refractory psychiatry unit for 3 years for severe refractory West Virginia, USA mania who developed multiple episodes of severe mania. Medical history includes hypothyroidism, Correspondence to hypothermia associated with several psychiatric coronary artery disease, atrial fibrillation and hyper- Dr Suzanne Holroyd, medications including olanzapine, quetiapine, valproic tension. Her mania is characterised by grandiose holroyds@ marshall. edu acid and oxcarbazepine. These episodes resolved and paranoid delusions, aggressive and hypersexual following discontinuation of the agents. The patient behaviours. She had been treated with lithium Accepted 30 October 2017 had never experienced hypothermia before, despite 300 mg/day, VPA 750 mg/day, olanzapine 5 mg/day, having been on these or similar agents for many years. quetiapine 600 mg/day and lorazepam 1 mg pro With traditional treatments for mania not feasible, re nata (PRN). Her non-psychiatric medications other medications were used to treat her including included amlodipine 2.5 mg/day, aspirin 325 mg/ lithium, clonazepam, gabapentin and the novel protein day, levothyroxine 88 µg/day, loratadine 10 mg/day, kinase c inhibitor tamoxifen.
    [Show full text]